DNA vs LCTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 28, 2026

DNA

45.0
AI Score
VS
LCTX Wins

LCTX

50.4
AI Score

Investment Advisor Scores

DNA

45score
Recommendation
HOLD

LCTX

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA LCTX Winner
Revenue 39.63M 2.79M DNA
Net Income -129.30M -3.33M LCTX
Net Margin -326.3% -119.2% LCTX
Operating Income -129.92M -16.52M LCTX
ROE -30.8% -5.5% LCTX
ROA -13.1% -3.1% LCTX
Total Assets 990.05M 106.22M DNA
Cash 84.53M 37.35M DNA
Current Ratio 4.57 6.61 LCTX
Free Cash Flow -95.51M -15.48M LCTX

Relative Price Performance (Last 90 Days)

DNA 1M: +11.4% · 3M: +64.6% LCTX 1M: +9.8% · 3M: -6.3%

Current Technical Phase

DNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (18.6% over 20 days), RSI 65

RSI (14): 64.6 · Price: $13.32

LCTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 57.1 · Price: $1.04

Fundamentals Snapshot

Metric DNA LCTX
Market Cap — —
Forward P/E -4.6 -7.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% -0.6%
Gross Margin 0.7% -0.6%
Operating Margin -2.8% -8.3%
EPS -5.06 -0.18
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, LCTX is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.